Nicotine Replacement for Withdrawal Prophylaxis (NOT for ICU use) (1893)

| | Version: 7 Gen: 8/25/2025 | |
|--|--|---|
| Location: | | |
| | | |
| General | | |
| Nursing | | |
| Tobacco Cessation Education | | |
| Tobacco cessation education Or patient to stop patch if patient is smoking Medications | nce, 1, Occurrences, Routine, Nurse to provide toing. | obacco cessation education. RN to inform |
| ☐ Transdermal Nicotine Patch | | |
| Transdermal Nicotine Patch | | |
| Dosing suggestions for nicotine p | patch: | |
| | Number of cigarettes per day | Dosing |
| | | (mg/day) |
| Less than 10, patients with | h heart disease <i>or</i> weighing less than 100 | . 0/ |
| | 10-20 21-40 | 14-21 21-42 |
| | Greater than 40 | 42+ |
| | Greater than 40 | 721 |
| | | |
| | | |
| O nicotine (NICODERM CQ) 7 mg/2 Time to remove patch: | 24 hr 1 patch, transdermal, daily, 24.000 Hours | |
| | patch. Rotate application site. Nurse to inform pa | itient to remove patch if they are smoking. |
| | g/24 hr 1 patch, transdermal, daily, 24.000 Hours | , , , |
| Time to remove patch: | patch. Rotate application site. Nurse to inform pa | itient to remove patch if they are smoking. |
| | 1/24 hr 1 patch, transdermal, daily, 24.000 Hours | . , |
| Time to remove patch: | patch. Rotate application site. Nurse to inform pa | itient to remove patch if they are smoking. |
| O nicotine (NICODERM CQ) 42 mg | g/24 hr 2 patch, transdermal, daily, 24.000 Hours | |
| Time to remove patch: Apply two new patches daily and remo | ove old patches. Rotate application site. Nurse to i | inform patient to remove patches if they |
| are smoking. For tobacco users willing to quit | | |
| For tobacco users willing to quit | | |
| _ | | |
| ✓ buPROPion SR (WELLBUTF | • | P), |
| contraindicated in patients at | (Wellbutrin/Zyban) or varenicline (Chantix ⁰ increased risk for seizures or on monoami good changes such as depression and suic | ne oxidase inhibitors. Monitor |
| Initiate bupropion SR 1 wee | ek prior to quit date. | |
| buPROPion SR (WELL | • | |
| • | t (WELLBUTRIN SR) 12 hr tablet 150 mg, oral, d | laily, 3, Days |
| Indication: | (WELLBUTRIN SR) 12 hr tablet 150 mg, oral, 2 | |
| Indication: | | , |
| O Severe Hepatic Dysfu | nction - buPROPION SR (WELLBUTRIN/ZYBAI | N) |
| buPROPion SR Indication: | t (WELLBUTRIN SR) 12 hr tablet 150 mg, oral, e | every other day |
| O Patients on Hemodialy | ysis - buPROPion SR (WELLBUTRIN/ZYBAN) | |
| buPROPion SR Indication: | (WELLBUTRIN SR) 12 hr tablet 150 mg, oral, e | every 3 days |
| Sign: | Printed Name: | Date/Time: |

Page 1 of 2

| $oxedsymbol{oxed}$ Transdermal Nicotine Patch | | Transdermal | Nicotine | Patch |
|---|--|-------------|----------|-------|
|---|--|-------------|----------|-------|

Dosing suggestions for nicotine patch:

| Number of cigarettes per day | |
|---|-------|
| Less than 10, patients with heart disease <i>or</i> weighing less than 100 pounds (45 kg) | 7-14 |
| 10-20 | 14-21 |
| 21-40 | 21-42 |
| Greater than 40 | 42+ |

| | Greater than 10 | 12 |
|--------------|--|----------------|
| | | |
| | onicotine (NICODERM CQ) 7 mg/24 hr 1 patch, transdermal, daily, 24.000 Hours Time to remove patch: | |
| | Apply new patch daily and remove old patch. Rotate application site. Nurse to inform patient to remove pat smoking. | ch if they are |
| | O nicotine (NICODERM CQ) 14 mg/24 hr 1 patch, transdermal, daily, 24.000 Hours Time to remove patch: | |
| | Apply new patch daily and remove old patch. Rotate application site. Nurse to inform patient to remove patsmoking. | ch if they are |
| | O nicotine (NICODERM CQ) 21 mg/24 hr 1 patch, transdermal, daily, 24.000 Hours Time to remove patch: | |
| | Apply new patch daily and remove old patch. Rotate application site. Nurse to inform patient to remove pats smoking. | ch if they are |
| | O nicotine (NICODERM CQ) 42 mg/24 hr 2 patch, transdermal, daily, 24.000 Hours Time to remove patch: | |
| | Apply two new patches daily and remove old patches. Rotate application site. Nurse to inform patient to repatches if they are smoking. | move |
| hen pre | icline (CHANTIX) tablet escribing varenicline (CHANTIX) - monitor patients for behavioral and mood changes such as on and suicidal ideations. Dosing adjustment not necessary in patients with hepatic dysfuncti | s on. |
| \circ v | arenicline (CHANTIX): CrCl > 50 mL/min | |
| | varenicline (CHANTIX) tablet 0.5 mg, oral, daily, 3, Days Give after meals. | |
| | varenicline (CHANTIX) tablet 0.5 mg, oral, 2 times daily, 4, Days Give after meals. | |
| | varenicline (CHANTIX) tablet 1 mg, oral, 2 times daily Give after meals. | |
| \bigcirc v | arenicline (CHANTIX): CrCl greater than or equal to 50 mL/min | |
| | ✓ varenicline (CHANTIX) tablet 0.5 mg, oral, daily Give after meals. For patients with CrCl less than or equal to 50 mL/min. | |
| | ✓ varenicline (CHANTIX) tablet 0.5 mg, oral, 2 times daily Give after meals. For patients with CrCl less than or equal to 50 mL/min. | |
| \bigcirc v | arenicline (CHANTIX): ESRD | |
| | varenicline (CHANTIX) tablet .5 , oral Give after meals. Patient with ESRD. | |
| | | |

_ Date/Time: Page 2 of 2 Printed Name: